Baebies Inc., Durham, NC, USA
RAPID NEAR-PATIENT ID/AST
Diagnostic for Neonatal Sepsis
Baebies is developing a novel small footprint diagnostic instrument for rapid diagnosis of neonatal sepsis. The system provides a two-fold diagnosis. First a rapid test of 15 minutes to determine if the infection is due to bacteria. This is followed by a post blood culture rapid 15-minute molecular test for pathogen identification and antibiotic sensitivity. The speed and sensitivity of these tests is underpinned by Baebies’ patented digital microfluidic technology. With a focus on small volumes and rapid testing, Baebies aims to meet an important medical need for neonates.
Current Development Stage: Feasibility
CARB-X Investment: Initial investment of up to $3.9m with potential option payments up to $7.7m.
Initial CARB-X Investment Date: February 1, 2021